Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that have reported quarterly revenues of at least $2 billion, only one posted a year-over-year decline. And that decline came with a caveat.
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that have reported quarterly revenues of at least $2 billion, only one posted a year-over-year decline. And that decline came with a caveat.
